New York, Jan 7, 2026, 12:57 (EST) — Regular session
- Wave Life Sciences shares were up 4.4% in midday trade.
- Traders pointed to fresh obesity trial data from Arrowhead that hit the same gene target Wave is chasing.
- The next checkpoint is Wave’s Jan. 13 slot at the J.P. Morgan Healthcare Conference.
Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE.
The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity candidates aimed at INHBE or its receptor, ALK7. Arrowhead said its ARO-INHBE nearly doubled weight loss when paired with Eli Lilly’s tirzepatide, and drove what an outside expert called “dramatic and rapid reductions in visceral fat,” the fat that builds around organs. RNAi, short for RNA interference, is a gene-silencing approach that blocks cells from making a specific protein. https://arrowheadpharma.com/news-press/arr…
A note from Clear Street also helped keep Wave in focus, according to Investing.com. The firm reiterated a buy rating and a $47 price target, arguing Arrowhead’s readout supported the INHBE mechanism and could be additive to GLP-1 drugs, the dominant class of weight-loss medicines, while warning that key unknowns remain on use cases and durability.
Wave is developing WVE-007, its own INHBE-targeting drug, using a small interfering RNA designed to shut down a gene signal in the liver. In December, Wave reported interim Phase 1 data showing a 9.4% reduction in visceral fat at three months after a single 240 mg dose, alongside a rise in lean mass; CEO Paul Bolno said the fat loss was “on par with GLP-1s” without muscle loss. Angela Fitch, chief medical officer at knownwell, said “the goal is to become leaner, not simply lighter,” as she described the early signal. https://www.globenewswire.com/news-release…
Wednesday’s move came alongside a broader biotech bid, with the SPDR S&P Biotech ETF up about 2.4%. Arrowhead slid 7.5% after jumping a day earlier, while Wave hit an intraday high of $16.12.
Wave also has a calendar catalyst close by. The company said Bolno will present at the J.P. Morgan Healthcare Conference on Jan. 13, a venue where biotech CEOs often revisit trial timelines and cash needs.
But the trade carries obvious risks: the Arrowhead combo results were drawn from small patient numbers, with some fat measurements coming from just three people, BioSpace reported. Wave’s own INLIGHT study is still early, and higher-dose and longer follow-up data could soften the story just as quickly as they strengthen it.
